Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved ...

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon ...

By genetically manipulating mice with black fur, the researchers identified two key players: B-Raf and C-Raf proteins. These proteins are required for melanocyte stem cell self-maintenance and ...

In 2002, investigators at the Sanger Institute discovered that mutations in the gene encoding the serine–threonine protein kinase B-RAF (BRAF) occurred in more than 60% of melanomas initially ...

PLX4032 (Plexxikon; RG7204, Roche Pharmaceuticals) is a potent inhibitor of BRAF with the V600E mutation. Preclinical studies showed that PLX4032 and its analogue PLX4720 inhibit the kinase ...